Endpoints NewsOriginal article
UniQure sinks as Huntington's gene therapy appears to show waning benefit over time
Data ReadoutnegativeNegative
AI Analysis
Summary
UniQure's experimental Huntington's disease gene therapy showed waning benefit in additional follow-up data, falling short of earlier expectations. The disappointing results led to a significant decline in the company's stock price.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Additional year of follow-up data shows experimental Huntington's disease gene therapy may have less benefit than originally thought, suggesting waning benefit over time
Importance:7/10
Sentiment:
-0.85
gene therapyHuntington's diseasenegative dataclinical trialstock decline
Related Companies
Read the original article
Published by Endpoints News on September 29, 2026 2:23 PM